Search research articles
Contact Us
Filters
Showing results (71-80 of 161) with videos related to
Page
of 17
Sort By:
Journal for Immunotherapy of Cancer
|
July 24, 2021
CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study
Rachel E Sanborn, Omid Hamid, Elisabeth Ge de Vries, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 11, 2023
Development of a Practical Nomogram for Personalized Anemia Management in Patients Treated with Ataxia Telangiectasia and Rad3-related Inhibitor Camonsertib
Ezra Rosen, Timothy A Yap, Elizabeth K Lee, et al.
British Journal of Cancer
|
April 29, 2023
A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer
Rebecca Kristeleit, Ruth Plummer, Robert Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 3, 2008
Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors
Ruth Plummer, Christopher Jones, Mark Middleton, et al.
Health Technology Assessment (Winchester, England)
|
March 21, 2024
Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis: the EASI-SWITCH RCT
Vicky Coyle, Caroline Forde, Richard Adams, et al.
Trials
|
May 29, 2020
Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis (the EASI-SWITCH trial): study protocol for a randomised controlled trial
Caroline Forde, Ronan McMullan, Mike Clarke, et al.
British Journal of Cancer
|
May 27, 2016
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer
Yvette Drew, Jonathan Ledermann, Geoff Hall, et al.
British Journal of Cancer
|
September 27, 2017
SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting
Alastair Greystoke, Nicola Steele, Hendrik-Tobias Arkenau, et al.
Molecular Cancer Therapeutics
|
January 29, 2009
Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines
Michelle J Clarke, Evan A Mulligan, Patrick T Grogan, et al.
British Journal of Cancer
|
March 23, 2016
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer
Yvette Drew, Jonathan Ledermann, Geoff Hall, et al.
Page
of 17
Search research articles
Search
Showing results (71-80 of 161) with videos related to
Sort By:
Page
of 17
Journal for Immunotherapy of Cancer
|
July 24, 2021
CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study
Rachel E Sanborn, Omid Hamid, Elisabeth Ge de Vries, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 11, 2023
Development of a Practical Nomogram for Personalized Anemia Management in Patients Treated with Ataxia Telangiectasia and Rad3-related Inhibitor Camonsertib
Ezra Rosen, Timothy A Yap, Elizabeth K Lee, et al.
British Journal of Cancer
|
April 29, 2023
A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer
Rebecca Kristeleit, Ruth Plummer, Robert Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 3, 2008
Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors
Ruth Plummer, Christopher Jones, Mark Middleton, et al.
Health Technology Assessment (Winchester, England)
|
March 21, 2024
Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis: the EASI-SWITCH RCT
Vicky Coyle, Caroline Forde, Richard Adams, et al.
Trials
|
May 29, 2020
Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis (the EASI-SWITCH trial): study protocol for a randomised controlled trial
Caroline Forde, Ronan McMullan, Mike Clarke, et al.
British Journal of Cancer
|
May 27, 2016
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer
Yvette Drew, Jonathan Ledermann, Geoff Hall, et al.
British Journal of Cancer
|
September 27, 2017
SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting
Alastair Greystoke, Nicola Steele, Hendrik-Tobias Arkenau, et al.
Molecular Cancer Therapeutics
|
January 29, 2009
Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines
Michelle J Clarke, Evan A Mulligan, Patrick T Grogan, et al.
British Journal of Cancer
|
March 23, 2016
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer
Yvette Drew, Jonathan Ledermann, Geoff Hall, et al.
Page
of 17